Previous close | 359.20 |
Open | 361.80 |
Bid | 364.60 x 0 |
Ask | 365.00 x 0 |
Day's range | 360.00 - 368.40 |
52-week range | 355.80 - 918.50 |
Volume | |
Avg. volume | 67,397 |
Market cap | 6.352B |
Beta (5Y monthly) | 1.42 |
PE ratio (TTM) | 37.21 |
EPS (TTM) | 9.81 |
Earnings date | 09 May 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 09 Oct 2020 |
1y target est | 1,000.00 |
ANNOUNCEMENT NO. 2349 February 2023Interim report for the first half of 2022/23 15% revenue growth and DKK 145 million operating profit (+25%) for the first half following a challenging second quarter Steen Søndergaard, CEO: “Following a very satisfactory 2021/22 with historically high revenue and operating profit growth rates, revenue for the first half of 2022/23 unfortunately disappointed, despite 15% growth. Second quarter sales of instruments, particularly in the North American market, were
ANNOUNCEMENT NO. 233 14 December 2022 Management change Steen Søndergaard has announced that he wants to resign from his position as CEO of ChemoMetec A/S. It has been agreed that Steen Søndergaard remains in his position until a replacement has been found, however with resignation during the calendar year 2023 and possibly no later than 30 June 2023. The search for a new CEO has been initiated, and the Board of Directors expects to announce the name of the new CEO during the first quarter of 20
ANNOUNCEMENT NO. 232 Trading statement for Q1 2022/23 (1 July - 30 September 2022) Good start to the fiscal year with 34% revenue growth The financial year 2022/23 is off to a good start with revenue up 34% in the first quarter to DKK 113.8 million from DKK 85.0 million in the year-earlier period. While all product segments recorded growth, the North American market remains the main geographical growth driver. EBITDA amounted to DKK 65.2 million, a year-on-year increase of 50%, for an EBITDA mar